– SWITZERLAND, Zug – Berlin Heals Holding AG, a Swiss medical technology company, today announced the appointments of Dr. Felix Baader and Roland Diggelmann to its Board of Directors.
“We are very excited to welcome Dr. Baader and Mr. Diggelmann, two medtech experts with a wealth of experience and strategic vision, to the Board of Directors of Berlin Heals. Being able to bring two new, high-profile board members into the company now is a significant step for us,” said Board Chairman, Dr. Ulf Berg.
About Dr. Felix Baader
Dr. Felix Baader held various key positions in the healthcare and technology sectors over the last 30 years, including at Roche Diagnostics, Biotronik and Philips and today holds board mandates at Congenius, Valtronic Holding and Bibus Group AG, among other ventures.
Dr. Felix Baader commented: “I am honoured to be part of Berlin Heals’ Board of Directors at this important stage. The company has a revolutionary product that will massively and sustainably improve the quality of life of many heart patients.”
About Roland Diggelmann
As former CEO of Roche Diagnostics and British medtech company, Smith & Nephew, Roland Diggelmann brings valuable know-how to Berlin Heals. He has also successfully applied his experience in strategic development and M&A as a highly respected medtech investor and Non-Executive Director at Sonova, Mettler Toledo and several start-ups.
“Berlin Heals’ C-MIC device is a game-changer for dilated cardiomyopathy therapy and has significant market potential; it not only reduces hospital stay duration, but also relieves the burden on health insurers and hospitals,” said Roland Diggelmann.
About Berlin Heals Holding AG
Berlin Heals Holding AG is a joint stock company founded in 2014 byNon- well-known heart specialist, Dr. Johannes Müller, and entrepreneur Marko Bagaric. The company has developed a novel therapy – “C-MIC” (Cardiac Microcurrent) – which uses a constant microcurrent to rapidly and sustainably improve inflammatory parameters within the heart of cardiac insufficiency patients. Recruitment of patients into the ongoing CE trial is currently approximately 60%. To date, over 35 C-MIC devices have been successfully implanted and continue to show promising results.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.